It is the quickly growing field of science that studies the effects of individual genetic variations on drug response.
The end result of pharmacogenomics research will be to match an individual's genetic profile to the best drug that will do the most good with the least harm to the body.
In 2000, the Institute of Medicine published To Err Is Human: Building a Safer Health System which identified adverse reactions to prescribed drugs as a leading cause of death in the United States.
Any adverse relationship between drugs and genes runs along a continuum, depending upon the individual and the medication:
A person's genetic profile influences where on this continuum he or she will fall when taking a particular medication.
Pharmacogenomics research will enable patients to receive the best possible individualized drug treatment based upon their genotypes. One predicted sequence of developments in the field is presented here:
|
Establishment of prescribing guidelines, based on clinical studies, for drugs that are subject to substantial polymorphism metabolism. |
|
Prescribing advice will relate dose to genotype and will highlight the possibility of drug interactions when multiple drugs are prescribed concomitantly. |
|
Establishment and recording of individual patient genotypes -- that is, personal pharmacogenetic profiles. |
|
Pharmacogenetic testing will substantially reduce the need for hospitalization, and its associated costs, because of adverse drug reactions. |
|
Development of new drugs for patients with specific genotypes -- that is, drug stratification. |
Source: Wolf CR, Smith G., and Smith R. "Science, Medicine, and the Future: Pharmacogenetics." British Medical Journal; April 8, 2000; 320: 987. PDF version (210 KB, 4 pages, Requires Adobe Reader)